ATE435302T1 - Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken - Google Patents
Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkrankenInfo
- Publication number
- ATE435302T1 ATE435302T1 AT03747881T AT03747881T ATE435302T1 AT E435302 T1 ATE435302 T1 AT E435302T1 AT 03747881 T AT03747881 T AT 03747881T AT 03747881 T AT03747881 T AT 03747881T AT E435302 T1 ATE435302 T1 AT E435302T1
- Authority
- AT
- Austria
- Prior art keywords
- rivastigmine
- determination
- treatment success
- apoe genotype
- predicting treatment
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 101150037123 APOE gene Proteins 0.000 title 1
- 102100029470 Apolipoprotein E Human genes 0.000 title 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 title 1
- 229960004136 rivastigmine Drugs 0.000 title 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 abstract 1
- 108010025628 Apolipoproteins E Proteins 0.000 abstract 1
- 102000013918 Apolipoproteins E Human genes 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40169402P | 2002-08-07 | 2002-08-07 | |
| PCT/EP2003/008719 WO2004015140A1 (en) | 2002-08-07 | 2003-08-06 | Methods for the treatment of dementia based on apo e genotype |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435302T1 true ATE435302T1 (de) | 2009-07-15 |
Family
ID=31715721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03747881T ATE435302T1 (de) | 2002-08-07 | 2003-08-06 | Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20060160079A1 (de) |
| EP (1) | EP1529116B1 (de) |
| JP (1) | JP2005534710A (de) |
| CN (1) | CN1681941A (de) |
| AT (1) | ATE435302T1 (de) |
| AU (1) | AU2003266967B2 (de) |
| BR (1) | BR0313588A (de) |
| CA (1) | CA2494585A1 (de) |
| DE (1) | DE60328198D1 (de) |
| DK (1) | DK1529116T3 (de) |
| ES (1) | ES2327914T3 (de) |
| IL (1) | IL166466A0 (de) |
| PT (1) | PT1529116E (de) |
| WO (1) | WO2004015140A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6835750B1 (en) | 2000-05-01 | 2004-12-28 | Accera, Inc. | Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II |
| WO2006014755A2 (en) * | 2004-07-20 | 2006-02-09 | Wyeth | Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease |
| CA2596523A1 (en) * | 2005-01-31 | 2006-08-10 | Perlegen Sciences, Inc. | Genetic basis of alzheimer's disease and diagnosis and treatment thereof |
| US7740593B2 (en) | 2005-12-09 | 2010-06-22 | Senorx, Inc | Guide block for biopsy or surgical devices |
| PT2179284T (pt) | 2007-07-31 | 2016-12-30 | Accera Inc | Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| CN105640931A (zh) | 2008-07-03 | 2016-06-08 | 艾克塞拉公司 | 用于治疗神经性障碍的乙酰乙酸的单甘油酯及其衍生物 |
| WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
| WO2015020523A1 (en) | 2013-08-07 | 2015-02-12 | Stichting Vu-Vumc | Biomarkers for early diagnosis of alzheimer's disease |
| WO2018175581A1 (en) | 2017-03-21 | 2018-09-27 | The Jackson Laboratory | A GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 MOUSE Trem2.p.R47H AND METHODS OF USE THEREOF |
| HRP20210634T1 (hr) | 2017-05-24 | 2021-05-28 | H. Lundbeck A/S | Kombinacija 5-ht6 antagonist receptora i inhibitora acetilkolinesteraze za uporabu u liječenju alzheimerove bolesti u subpopulaciji pacijenta koji nosi apoe4 alela |
| US20210195879A1 (en) * | 2018-06-21 | 2021-07-01 | The Jackson Laboratory | Genetically modified mouse models of alzheimer's disease |
| EP3931349B8 (de) * | 2019-02-28 | 2025-01-15 | The Rockefeller University | Apoe-genotyping in der krebsprognose und -therapie |
| TWI888447B (zh) | 2019-12-13 | 2025-07-01 | 美商因思博納公司 | 金屬鹽及其用途 |
| CN117886933A (zh) * | 2023-12-28 | 2024-04-16 | 上海良润生物医药科技有限公司 | 一种载脂蛋白e检测试剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE625212T1 (de) * | 1992-10-13 | 2000-11-02 | Duke University, Durham | Verfahren zum entdecken von krankheit von alzheimer. |
| CA2111503A1 (en) * | 1993-12-15 | 1995-06-16 | Mcgill University | Apolipoprotein e polymorphism and alzheimer's disease |
| FR2765591B1 (fr) * | 1997-07-01 | 2002-08-09 | Pasteur Institut | Procede de diagnostic de la maladie d'alzheimer |
| CO4980891A1 (es) * | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
| JP2000069963A (ja) * | 1998-08-31 | 2000-03-07 | Igaku Seibutsugaku Kenkyusho:Kk | アポリポプロテインe4特異モノクローナル抗体 |
| HUP0103883A3 (en) * | 1998-10-01 | 2002-11-28 | Novartis Ag | New sustained release oral formulations |
| ATE314343T1 (de) * | 2000-06-30 | 2006-01-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
-
2003
- 2003-08-06 AT AT03747881T patent/ATE435302T1/de not_active IP Right Cessation
- 2003-08-06 AU AU2003266967A patent/AU2003266967B2/en not_active Ceased
- 2003-08-06 PT PT03747881T patent/PT1529116E/pt unknown
- 2003-08-06 DK DK03747881T patent/DK1529116T3/da active
- 2003-08-06 EP EP03747881A patent/EP1529116B1/de not_active Expired - Lifetime
- 2003-08-06 ES ES03747881T patent/ES2327914T3/es not_active Expired - Lifetime
- 2003-08-06 JP JP2004526899A patent/JP2005534710A/ja active Pending
- 2003-08-06 CA CA002494585A patent/CA2494585A1/en not_active Abandoned
- 2003-08-06 US US10/523,047 patent/US20060160079A1/en not_active Abandoned
- 2003-08-06 DE DE60328198T patent/DE60328198D1/de not_active Expired - Lifetime
- 2003-08-06 CN CNA038212528A patent/CN1681941A/zh active Pending
- 2003-08-06 WO PCT/EP2003/008719 patent/WO2004015140A1/en active Application Filing
- 2003-08-06 BR BR0313588-8A patent/BR0313588A/pt not_active Application Discontinuation
-
2005
- 2005-01-24 IL IL16646605A patent/IL166466A0/xx unknown
-
2007
- 2007-11-16 US US11/941,420 patent/US20080214662A1/en not_active Abandoned
-
2010
- 2010-06-03 US US12/793,436 patent/US20100240744A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20100240744A1 (en) | 2010-09-23 |
| BR0313588A (pt) | 2005-07-12 |
| DE60328198D1 (de) | 2009-08-13 |
| ES2327914T3 (es) | 2009-11-05 |
| CA2494585A1 (en) | 2004-02-19 |
| IL166466A0 (en) | 2006-01-15 |
| JP2005534710A (ja) | 2005-11-17 |
| US20080214662A1 (en) | 2008-09-04 |
| EP1529116A1 (de) | 2005-05-11 |
| PT1529116E (pt) | 2009-09-10 |
| AU2003266967A1 (en) | 2004-02-25 |
| US20060160079A1 (en) | 2006-07-20 |
| EP1529116B1 (de) | 2009-07-01 |
| AU2003266967B2 (en) | 2006-11-16 |
| CN1681941A (zh) | 2005-10-12 |
| WO2004015140A1 (en) | 2004-02-19 |
| DK1529116T3 (da) | 2009-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE435302T1 (de) | Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken | |
| ATE526041T1 (de) | Verfahren zur hemmung okularer vorgänge | |
| MX2007006529A (es) | Seleccionar pacientes para terapia con un inhibidor her. | |
| ATE488251T1 (de) | Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen | |
| ATE426043T1 (de) | Verfahren zur identifizierung des brustkrebsrisikos | |
| ATE519503T1 (de) | Verfahren zur behandlung von patienten mit hepatitis c | |
| ATE503563T1 (de) | Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren | |
| DE602005023517D1 (de) | Verfahren zur bestimmung von genotoxizität | |
| ATE397098T1 (de) | Verfahren zur diagnostik von eierstock endometriose | |
| WO2007006862A3 (en) | Method and kit for detecting a risk of coronary heart disease | |
| ATE469245T1 (de) | Auf genetischem targeting basierendes verfahren zur behandlung mit bucindolol | |
| WO2005014846A3 (en) | Methods for identifying risk of breast cancer and treatments thereof | |
| MXPA05008793A (es) | Metodos para la prediccion de posibilidad de suicidio durante el tratamiento. | |
| ATE487947T1 (de) | Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse | |
| DE602005023363D1 (de) | Vorrichtung und Verfahren zur Authentifizierung von Blutgefässen | |
| WO2006028999A3 (en) | Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy | |
| DE602005020113D1 (de) | Verfahren zur behandlung von akuten rhinosinusitis | |
| ATE432996T1 (de) | Verfahren zur bestimmung des bodenzustands | |
| WO2006053955A3 (en) | Method and kit for detecting a risk of essential arterial hypertension | |
| ATE543429T1 (de) | Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür | |
| ATE443262T1 (de) | Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen | |
| WO2005118834A3 (en) | Methods for identifying risk of breast cancer and treatment thereof | |
| WO2006053252A3 (en) | Methods of treating hematological malignancies with nucleoside analog drugs | |
| DE60319719D1 (de) | Verfahren zur voraussage der erhöhung von cholesterin während einer immunosuppresiven therapie | |
| ATE483983T1 (de) | Verfahren zur diagnose von chronischem stress und verwandten erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1529116 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |